3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Neoplasm Metastasis
1
Carcinoma, Squamous Cell
1
Interventions
pembrolizumab
11
Cisplatin
11
Carboplatin
7
Radiotherapy
6
Cetuximab
6
Docetaxel
5
Surveys and Questionnaires
3
Radiotherapy, Intensity-Modulated
3
Paclitaxel
3
Nivolumab
3
Cyclophosphamide
3
fludarabine
2
cemiplimab
2
atezolizumab
2
aldesleukin
2
Surgical Procedures, Operative
2
Standard of Care
2
Radiation
2
Magnetic Resonance Spectroscopy
2
Fluorouracil
2
Drug Therapy
2
vistusertib
1
toripalimab
1
sitravatinib
1
palbociclib
1
osimertinib
1
olaparib
1
niraparib
1
lenvatinib
1
fludarabine phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Squamous Cell
×
ficlatuzumab
×
90 days
×
Clear all
NCT06064877
2026-04-09
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3
Recruiting
410 enrolled